Phase II Study of CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Condition:   Peripheral T Cell Lymphoma Intervention:   Biological: ATLCAR.CD30 T cells Sponsor:   UNC Lineberger Comprehensive Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials